



# Entresto in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

CARDIOLOGY · HEART FAILURE

## The clinical situation

Entresto (sacubitril/valsartan) is an FDA-approved oral angiotensin receptor-neprilysin inhibitor (ARNI) indicated to reduce cardiovascular death and heart-failure hospitalisation in chronic heart failure across the ejection-fraction spectrum. Manufactured by Novartis. Standard dosing titrates from 24/26 mg or 49/51 mg to the target 97/103 mg twice daily, with baseline and interval potassium, creatinine, and blood-pressure monitoring; ambient-storage oral tablet.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating cardiologist confirms heart-failure diagnosis, documents prior ACEi/ARB washout, and writes the ARNI initiation plan.
- 2 Treating centre confirmed.** A Saudi tertiary cardiology centre in Riyadh, Jeddah, or Dhahran accepts the case and writes the prescription.
- 3 SFDA named-patient application.** Clinical rationale, patient reference, and product details are filed; SFDA NPP electronic submission.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-temperature shipment.
- 5 Arrival & administration.** Patient begins twice-daily oral dosing with physician-guided titration; labs and blood pressure rechecked at 1-2 and 4-week intervals.

### Indicative economics

**Reference US cash-pay range:** USD 650–800 per 30-day supply. SFDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

### Indicative first-dose timing

**7–14 days** from a complete SFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review. **Logistics.** Ambient-temperature shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating cardiologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Entresto × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/entresto-saudi-arabia.html](https://reservemed.com/access-guides/entresto-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team